LOUISVILLE, CO, October 25, 2007 – GlobeImmune, Inc. announced today results from research on its GI-10001 Tarmogen®, which is being investigated for the treatment of drug resistant chronic myelogenous leukemia (CML). Leukemia driven by the Bcr-Abl T315I mutation, known as … Continue reading
GlobeImmune Announces Presentation of Pre-Clinical Data on GI-10001 for Chronic Myelogenous Leukemia
October 25, 2007